EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling

Hybride Closed-Loop-Systeme zur Blutzuckerkontrolle bei Typ-1-Diabetes: systematische Übersicht und ökonomische Modellierung

Asra Asgharzadeh iD, Mubarak Patel iD, Martin Connock iD, Sara Damery iD, Iman Ghosh iD, Mary Jordan iD, Karoline Freeman iD, Anna Brown iD, Rachel Court iD, Sharin Baldwin iD, Fatai Ogunlayi iD, Chris Stinton iD und 2 weitere

Health Technology Assessment · 2024-12 · 1-190

DOI: 10.3310/jypl3536 ↗

Auf einen Blick

Randomisierte Studien zeigen für hybride Closed-Loop-Systeme bei Typ-1-Diabetes bessere glykämische Werte als die Vergleichstherapie. Die Kosten-Nutzen-Analyse ergab hohe Kosten pro QALY.

Fragestellung

Wie wirksam und kosteneffektiv sind hybride Closed-Loop-Systeme bei Menschen mit Typ-1-Diabetes, die trotz vorheriger Technologien Schwierigkeiten mit der Glukosekontrolle haben?

Methode

Systematische Übersicht zu klinischer Wirksamkeit und Kosteneffektivität; ökonomische Modellierung mit iQVIA CDM.

Ergebnisse

12 RCTs verglichen hybrid closed loop mit CSII + CGM. HbA1c sank um 0,28 % (95 %-KI −0,34 bis −0,21), Time in Range stieg um 8,6 (95 %-KI 7,03 bis 10,22), Hyperglykämiezeit sank um 7,2 (95 %-KI −8,89 bis −5,51).

Einschränkungen

Keine direkte Evidenz zu symptomatischen oder schweren Hypoglykämien; Unsicherheit der Langzeitmodellierung; ältere Modellvalidierungen überschätzten Komplikationen.

Schlussfolgerung der Autor:innen

Hybride Closed-Loop-Interventionen verbesserten in RCTs HbA1c, Time in Range und Hyperglykämie im Vergleich zu CSII + CGM signifikant.

Kernaussagen

  • HbA1c sank um 0,28 % gegenüber CSII + CGM
  • Time in Range stieg um 8,6
  • Kosten-Nutzen-Schätzer: £179,000 pro QALY

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2024-12. Verfasst von Asra Asgharzadeh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Cost-Benefit Analysis, Insulin Infusion Systems, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hybrid closed-loop systems are a new class of technology to manage type 1 diabetes mellitus. The system includes a combination of real-time continuous glucose monitoring from a continuous glucose monitoring device and a control algorithm to direct insulin delivery through an insulin pump. Evidence suggests that such technologies have the potential to improve the lives of people with type 1 diabetes mellitus and their families.

Aim

The aim of this appraisal was to assess the clinical effectiveness and cost-effectiveness of hybrid closed-loop systems for managing glucose in people who have type 1 diabetes mellitus and are having difficulty managing their condition despite prior use of at least one of the following technologies: continuous subcutaneous insulin infusion, real-time continuous glucose monitoring or flash glucose monitoring (intermittently scanned continuous glucose monitoring).

Methods

A systematic review of clinical effectiveness and cost-effectiveness evidence following predefined inclusion criteria informed by the aim of this review. An independent economic assessment using iQVIA CDM to model cost-effectiveness.

Results

The clinical evidence identified 12 randomised controlled trials that compared hybrid closed loop with continuous subcutaneous insulin infusion + continuous glucose monitoring. Hybrid closed-loop arm of randomised controlled trials achieved improvement in glycated haemoglobin per cent [hybrid closed loop decreased glycated haemoglobin per cent by 0.28 (95% confidence interval −0.34 to −0.21), increased per cent of time in range (between 3.9 and 10.0 mmol/l) with a MD of 8.6 (95% confidence interval 7.03 to 10.22), and significantly decreased time in range (per cent above 10.0 mmol/l) with a MD of −7.2 (95% confidence interval −8.89 to −5.51), but did not significantly affect per cent of time below range (< 3.9 mmol/l)]. Comparator arms showed improvements, but these were smaller than in the hybrid closed-loop arm. Outcomes were superior in the hybrid closed-loop arm compared with the comparator arm. The cost-effectiveness search identified six studies that were included in the systematic review. Studies reported subjective cost-effectiveness that was influenced by the willingness-to-pay thresholds. Economic evaluation showed that the published model validation papers suggest that an earlier version of the iQVIA CDM tended to overestimate the incidences of the complications of diabetes, this being particularly important for severe visual loss and end-stage renal disease. Overall survival’s medium-term modelling appeared good, but there was uncertainty about its longer-term modelling. Costs provided by the National Health Service Supply Chain suggest that hybrid closed loop is around an annual average of £1500 more expensive than continuous subcutaneous insulin infusion + continuous glucose monitoring, this being a pooled comparator of 90% continuous subcutaneous insulin infusion + intermittently scanned continuous glucose monitoring and 10% continuous subcutaneous insulin infusion + real-time continuous glucose monitoring due to clinical effectiveness estimates not being differentiated by continuous glucose monitoring type. This net cost may increase by around a further £500 for some systems. The Evidence Assessment Group base case applies the estimate of −0.29% glycated haemoglobin for hybrid closed loop relative to continuous subcutaneous insulin infusion + continuous glucose monitoring. There was no direct evidence of an effect on symptomatic or severe hypoglycaemia events, and therefore the Evidence Assessment Group does not include these in its base case. The change in glycated haemoglobin results in a gain in undiscounted life expectancy of 0.458 years and a gain of 0.160 quality-adjusted life-years. Net lifetime treatment costs are £31,185, with reduced complications leading to a net total cost of £28,628. The cost-effectiveness estimate is £179,000 per quality-adjusted life-year.

Conclusions

Randomised controlled trials of hybrid closed-loop interventions in comparison with continuous subcutaneous insulin infusion + continuous glucose monitoring achieved a statistically significant improvement in glycated haemoglobin per cent in time in range between 3.9 and 10 mmol/l, and in hyperglycaemic levels. Study registration This study is registered as PROSPERO CRD42021248512. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR133547) and is published in full in Health Technology Assessment ; Vol. 28, No. 80. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Cost-Benefit AnalysisInsulin Infusion SystemsBlood Glucose Self-MonitoringInsulinBlood GlucoseHumansHypoglycemic AgentsModels, EconomicGlycated HemoglobinQuality-Adjusted Life YearsRandomized Controlled Trials as TopicAlgorithms

Substanzen

InsulinBlood GlucoseHypoglycemic AgentsGlycated Hemoglobin

Autor:innen und Institutionen

  • Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
  • Murray Learning Centre, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • McMDC Ltd, Harrogate, UK.

ORCID-Profile: Asra Asgharzadeh, Mubarak Patel, Martin Connock, Sara Damery, Iman Ghosh, Mary Jordan, Karoline Freeman, Anna Brown, Rachel Court, Sharin Baldwin, Fatai Ogunlayi, Chris Stinton, Lena Al-Khudairy

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Asgharzadeh, A., Patel, M., Connock, M., Damery, S., Ghosh, I., Jordan, M., Freeman, K., Brown, A., Court, R., Baldwin, S., Ogunlayi, F., Stinton, C., Cummins, E., & Al-Khudairy, L. (2024). Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling. Health Technology Assessment, 1-190. https://doi.org/10.3310/jypl3536

Vancouver

Asgharzadeh A, Patel M, Connock M, Damery S, Ghosh I, Jordan M, et al. Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling. Health Technology Assessment. 2024:1-190. doi:10.3310/jypl3536

BibTeX
@article{Asgharzadeh2024,
  author = {Asgharzadeh, Asra and Patel, Mubarak and Connock, Martin and Damery, Sara and Ghosh, Iman and Jordan, Mary and Freeman, Karoline and Brown, Anna and Court, Rachel and Baldwin, Sharin and Ogunlayi, Fatai and Stinton, Chris and Cummins, Ewen and Al-Khudairy, Lena},
  title = {Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling},
  journal = {Health Technology Assessment},
  year = {2024},
  pages = {1--190},
  doi = {10.3310/jypl3536}
}
Kostenlos starten →